Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization
The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). This makes Lucentis, specifically designed for […]
